Cargando…

Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A

Among challenges of targeted therapies is the activation of alternative pro-survival signaling pathways in cancer cells, resulting in an acquired drug resistance. Cyclooxygenase-2 (COX-2) is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourn, Jennifer, Pandey, Sony, Uddin, Jashim, Marnett, Lawrence, Cekanova, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718263/ https://www.ncbi.nlm.nih.gov/pubmed/31497247 http://dx.doi.org/10.18632/oncotarget.27125

Ejemplares similares

Detection of carcinogen-induced bladder cancer by fluorocoxib A
por: Bourn, Jennifer, et al.
Publicado: (2019)

Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer
por: Cekanova, Maria, et al.
Publicado: (2020)

Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas
por: Uddin, Md. Jashim, et al.
Publicado: (2023)

Detection of Non-Melanoma Skin Cancer by in vivo Fluorescence Imaging with Fluorocoxib A
por: Ra, Hyejun, et al.
Publicado: (2015)

Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
por: Bourn, Jennifer, et al.
Publicado: (2018)

Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells
por: Pandey, Sony, et al.
Publicado: (2018)

The 2′-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor
por: Blobaum, Anna L., et al.
Publicado: (2013)

Synthesis of 5- and 6-Carboxy-X-rhodamines
por: Uddin, Md. Jashim, et al.
Publicado: (2008)

Design, Synthesis, and Structure–Activity Relationship Studies of Fluorescent Inhibitors of Cycloxygenase-2 as Targeted Optical Imaging Agents
por: Uddin, Md. Jashim, et al.
Publicado: (2013)

Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer
por: Uddin, Md. Jashim, et al.
Publicado: (2019)

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro
por: Smolensky, Dmitriy, et al.
Publicado: (2015)

[(123)I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation
por: Uddin, Md. Jashim, et al.
Publicado: (2010)

Inhibition of Diacylglycerol Lipase Impairs Fear Extinction in Mice
por: Cavener, Victoria S., et al.
Publicado: (2018)

The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase.
por: Akarasereenont, Pravit C, et al.
Publicado: (2002)

Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer
por: Smolensky, Dmitriy, et al.
Publicado: (2016)

Platelet-rich plasma affects the proliferation of canine bone marrow-derived mesenchymal stromal cells in vitro
por: Pandey, Sony, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Role of tyrosine kinases in bladder cancer progression: an overview
por: Zangouei, Amir Sadra, et al.
Publicado: (2020)

Inhibitors of Mitogen-Activated Protein Kinases Downregulate COX-2 Expression in Human Chondrocytes
por: Nieminen, Riina, et al.
Publicado: (2005)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Differential Sensitivity and Mechanism of Inhibition of COX-2 Oxygenation of Arachidonic Acid and 2-Arachidonoylglycerol by Ibuprofen and Mefenamic Acid
por: Prusakiewicz, Jeffery J., et al.
Publicado: (2009)

A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
por: Miyajima, Keiichiro, et al.
Publicado: (2023)

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder
por: Lee, Young H., et al.
Publicado: (2021)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Determination of biological activities of malabar spinach (Basellaalba) fruit extracts and molecular docking against COX-II enzyme
por: Nur, M. Ashaduzzaman, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
por: Gomez-Puerta, Jose A., et al.
Publicado: (2013)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
por: Ryan, John J.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g2mtkq5sqihn7lhm5ci2m6nnf6